Banque Pictet & Cie SA Sells 92 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Banque Pictet & Cie SA lowered its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 6.2% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,391 shares of the biopharmaceutical company’s stock after selling 92 shares during the period. Banque Pictet & Cie SA’s holdings in Alnylam Pharmaceuticals were worth $454,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in shares of Alnylam Pharmaceuticals by 2.5% during the 1st quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company’s stock worth $3,525,544,000 after purchasing an additional 323,206 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its stake in shares of Alnylam Pharmaceuticals by 0.8% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company’s stock worth $1,192,988,000 after purchasing an additional 33,696 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Alnylam Pharmaceuticals by 5.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company’s stock worth $946,466,000 after purchasing an additional 185,783 shares in the last quarter. American Century Companies Inc. raised its stake in shares of Alnylam Pharmaceuticals by 9.8% during the 1st quarter. American Century Companies Inc. now owns 1,760,435 shares of the biopharmaceutical company’s stock worth $475,353,000 after purchasing an additional 156,411 shares in the last quarter. Finally, Orbis Allan Gray Ltd raised its stake in shares of Alnylam Pharmaceuticals by 11.0% during the 1st quarter. Orbis Allan Gray Ltd now owns 1,634,923 shares of the biopharmaceutical company’s stock worth $441,462,000 after purchasing an additional 162,121 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on ALNY. Chardan Capital increased their price target on Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Morgan Stanley increased their price target on Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the company an “equal weight” rating in a research note on Friday, August 1st. UBS Group increased their price target on Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Wells Fargo & Company increased their price target on Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the company an “equal weight” rating in a research note on Friday, August 1st. Finally, Canaccord Genuity Group increased their price target on Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Twenty-four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $439.58.

Insider Activity at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 6,979 shares of the stock in a transaction on Monday, August 18th. The stock was sold at an average price of $453.27, for a total transaction of $3,163,371.33. Following the sale, the chief executive officer directly owned 56,221 shares of the company’s stock, valued at approximately $25,483,292.67. This represents a 11.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Colleen F. Reitan sold 18,000 shares of the stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $467.60, for a total value of $8,416,800.00. Following the sale, the director directly owned 775 shares in the company, valued at approximately $362,390. This trade represents a 95.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 75,594 shares of company stock worth $33,968,256 in the last quarter. 1.50% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY opened at $446.40 on Friday. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. The stock’s fifty day moving average price is $428.51 and its two-hundred day moving average price is $332.08. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $484.21. The firm has a market cap of $58.51 billion, a price-to-earnings ratio of -180.73 and a beta of 0.32.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The firm had revenue of $773.69 million for the quarter, compared to analyst estimates of $633.54 million. During the same period in the prior year, the firm posted ($0.13) EPS. The company’s revenue for the quarter was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.